| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/06/2002 | WO2002067960A1 Herbal compositions useful as chemopreventive and therapeutic agents |
| 09/06/2002 | WO2002067955A2 A process for the manufacture of a herbal composition comprising a matrine |
| 09/06/2002 | WO2002067946A1 The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy |
| 09/06/2002 | WO2002067941A2 Combination comprising a signal transduction inhibitor and an epothilone derivative |
| 09/06/2002 | WO2002067940A1 Application of phenazinone derivatives in preparing antitumor and antimetastases drugs |
| 09/06/2002 | WO2002067939A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 09/06/2002 | WO2002067937A1 Indoline and tetrahydro-quinolines as prodrugs for tumour treatment |
| 09/06/2002 | WO2002067932A1 Antihelminthic drugs as a treatment for hyperproliferative diseases |
| 09/06/2002 | WO2002067930A1 Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment |
| 09/06/2002 | WO2002067929A1 Furan fatty acids for increasing the efficiency of cytostatic treatment and/or radiotherapy |
| 09/06/2002 | WO2002067928A2 Metronomic dosing of taxanes for inhibiting tumor growth |
| 09/06/2002 | WO2002067919A1 Il-8 receptor antagonists |
| 09/06/2002 | WO2002067917A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 09/06/2002 | WO2002067913A1 (z)-styrylbenzylsulfones and pharmaceutical uses thereof |
| 09/06/2002 | WO2002067908A1 Novel dendritic polymers and their biomedical uses |
| 09/06/2002 | WO2002067893A2 Pharmaceutical formulation comprising bicalutamide |
| 09/06/2002 | WO2002067865A2 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof |
| 09/06/2002 | WO2002067862A2 Regulation of the ctl response by macrophage migration inhibitory factor |
| 09/06/2002 | WO2002067861A2 Oncolytic adenoviral vectors |
| 09/06/2002 | WO2002067851A2 Method for treating fibrotic diseases or other indications iiic |
| 09/06/2002 | WO2002067698A1 Process for the fractionation of cereal brans |
| 09/06/2002 | WO2002067688A1 Noninvasive measurements of chemical substances |
| 09/06/2002 | WO2002067681A1 Restore cancer-suppressing functions to neoplastic cells through dna hypomethylation |
| 09/06/2002 | WO2002067654A2 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| 09/06/2002 | WO2002048182A3 Interferon-alpha induced gene |
| 09/06/2002 | WO2002046216A3 Human sprouty-4 polypeptide |
| 09/06/2002 | WO2002046183A3 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 09/06/2002 | WO2002045654A3 Cancer preventative effect of morinda citrifolia |
| 09/06/2002 | WO2002043716A3 Method for regulating prostate gland volume with insulin sensitizers |
| 09/06/2002 | WO2002043648A8 Compounds active at the glucocorticoid receptor ii |
| 09/06/2002 | WO2002041882A3 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| 09/06/2002 | WO2002040517A3 M. tuberculosis chaperonin 60.1 and uses thereof |
| 09/06/2002 | WO2002040042A3 Method for optimally delivering virus to a solid tumor mass |
| 09/06/2002 | WO2002040037A3 M. tuberculosis chaperonin 60.1 and uses thereof |
| 09/06/2002 | WO2002040000A3 Use of cci-779 as an antineoplastic agent |
| 09/06/2002 | WO2002039958A3 Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| 09/06/2002 | WO2002039121A3 Methods for detecting the efficacy of anticancer treatments |
| 09/06/2002 | WO2002038563A3 Condensed pyrazindione derivatives as pde inhibitors |
| 09/06/2002 | WO2002036792A3 Dna expression vectors |
| 09/06/2002 | WO2002036771A3 Imaging, diagnosis and treatment of disease |
| 09/06/2002 | WO2002036580A3 Benzoxazole lpaat- beta inhibitors and uses thereof |
| 09/06/2002 | WO2002032868A3 2-substituted heterocyclic compounds and their use in treating multidrug resistance |
| 09/06/2002 | WO2002028860A3 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
| 09/06/2002 | WO2002022577A3 Hydroxamate derivatives useful as deacetylase inhibitors |
| 09/06/2002 | WO2002019972A3 Stabilized ascorbic acid solutions |
| 09/06/2002 | WO2002016574A3 Method for identifying peptides that can be specifically cleaved and the use of peptide sequences of this type |
| 09/06/2002 | WO2002012534A3 Bio-intermediates for use in the chemical synthesis of polyketides |
| 09/06/2002 | WO2002012250A3 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases |
| 09/06/2002 | WO2002010217A3 Endothelial cell expression patterns |
| 09/06/2002 | WO2002008475A3 Method for recovery of copper from sulfidic ore materials using super-fine grinding and medium temperature pressure leaching |
| 09/06/2002 | WO2002007823A3 Inhibition of mutagenic effects of carcinogens |
| 09/06/2002 | WO2002006465A9 7677, a novel human atpase family member and uses therefor |
| 09/06/2002 | WO2002005859A3 Radiotherapy |
| 09/06/2002 | WO2002002629A3 Grf2-binding proteins and applications thereof |
| 09/06/2002 | WO2001098363A3 Peptides for use in the immunotherapy of renal cell carcinoma |
| 09/06/2002 | WO2001095946A3 Combination product for carrying out a cytotoxic treatment in a mammal |
| 09/06/2002 | WO2001095937A3 Phytoestrogenic isoflavone compositions |
| 09/06/2002 | WO2001094612A3 Method for identifying medically valuable active substances |
| 09/06/2002 | WO2001092565A3 Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription |
| 09/06/2002 | WO2001091805A3 Compounds for targeting endothelial cells |
| 09/06/2002 | WO2001085785A3 Ph domain-interacting protein |
| 09/06/2002 | WO2001082910A3 Combination of progesterone and mifepristone for cancer therapy |
| 09/06/2002 | WO2001073093A3 Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| 09/06/2002 | WO2001072822B1 Genes involved in intestinal inflammatory diseases and use thereof |
| 09/06/2002 | WO2001064738A3 Heparin-binding amino acid sequences derived from human proteins facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 09/06/2002 | WO2001058915A8 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 09/06/2002 | WO2001051664A3 Method of detecting and characterizing a neoplasm |
| 09/06/2002 | WO2001048485A9 Selecting library members capable of binding to epitopes |
| 09/06/2002 | WO2001046253A9 A new polypeptide-calcitonin 11 and the polynucleotide encoding it |
| 09/06/2002 | WO2001032614A9 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 09/06/2002 | WO2001018035A9 Muc-1 derived peptides |
| 09/06/2002 | WO2001012674A9 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 09/06/2002 | WO2000078955A9 Epithelial cell growth inhibitors |
| 09/06/2002 | WO2000067761A9 Compositions and methods for identifying antigens which elicit an immune response |
| 09/06/2002 | CA2753395A1 Novel bifunctional chelating compounds containing hydroxamic acid residues |
| 09/06/2002 | CA2617312A1 Noninvasive measurement of chemical substances |
| 09/06/2002 | CA2617004A1 Noninvasive measurements of chemical substances |
| 09/06/2002 | CA2477043A1 Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer |
| 09/06/2002 | CA2475454A1 Aryl-n-cyanoguanidines and methods related thereto |
| 09/06/2002 | CA2439492A1 Tri-hybrid melanoma antigen |
| 09/06/2002 | CA2439463A1 Diaminoquinazoline esters for use as dihydrofolate reductade inhibitors |
| 09/06/2002 | CA2439366A1 Pharmaceutical formulation comprising bicalutamide |
| 09/06/2002 | CA2439335A1 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas |
| 09/06/2002 | CA2439303A1 Methods for identifying peptides which modulate a biological process |
| 09/06/2002 | CA2439299A1 Metronomic dosing of taxanes |
| 09/06/2002 | CA2439265A1 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 09/06/2002 | CA2439256A1 (z)-styrylbenzylsulfones and pharmaceutical uses thereof |
| 09/06/2002 | CA2439185A1 Vector constructs |
| 09/06/2002 | CA2439115A1 Novel oncolytic adenoviral vectors |
| 09/06/2002 | CA2439053A1 Hiv inhibiting n-aminoimidazole derivatives |
| 09/06/2002 | CA2438932A1 Compositions and methods for cancer prevention and treatment derived from inula britannica |
| 09/06/2002 | CA2438784A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 09/06/2002 | CA2438696A1 Polynucleotide formulation for enhanced intracellular transfer |
| 09/06/2002 | CA2438193A1 Novel dendritic polymers and their biomedical uses |
| 09/06/2002 | CA2437898A1 Interferon-alpha induced gene |
| 09/06/2002 | CA2437530A1 Symbiotic regenerative agent |
| 09/06/2002 | CA2437516A1 Heterocarpine, a human ghrh-binding protein |
| 09/06/2002 | CA2437114A1 Diamides which inhibit tryptase and factor xa activity |
| 09/06/2002 | CA2434727A1 Tricyclic quinolinone and tricyclic quinoline as androgen receptor modulator compounds |
| 09/06/2002 | CA2434690A1 Proteins, polynucleotides encoding them and methods of using the same |